HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights ...
Austin, Texas, United States, January 5th, 2026, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...
HeartBeam, Inc. , a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, ...
HeartBeam BEAT recently secured FDA 510(k) clearance for its first-of-its-kind, cable-free synthesized 12-lead ECG technology, marking a major inflection point in the company’s mission to modernize ...
(RTTNews) - HeartBeam, Inc. (BEAT), a medical technology company, announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company's groundbreaking ...
HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
Importance/background The 12-lead ECG is recommended in clinical guidelines for prehospital assessment of patients with suspected acute coronary syndrome (ACS) presenting to Emergency Medical Services ...
Twelve-lead ECGs, although standard in hospitals, can be bulky and impractical for home use. On the other hand, Apple Watch’s ECG app is easy to use, but it is limited in what it can detect because it ...
A 67-year-old man with a history of dilated cardiomyopathy and a left ventricular ejection fraction of 40% presents to his primary care provider for a routine physical examination. His vital signs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback